Spontaneous Regression in B Cell, Diffuse Large Cell Type Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 90 (1) ◽  
pp. 46-47 ◽  
Author(s):  
J. Tamura ◽  
T. Jinbo ◽  
H. Take ◽  
T. Matsushima ◽  
M. Sawamura ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Spontaneous Regression ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals t(3;22)(q27;q11): a novel translocation associated with diffuse non- Hodgkin's lymphoma [see comments]

Blood ◽  
1989 ◽  
Vol 74 (6) ◽  
pp. 1876-1879 ◽  
Author(s):  
K Offit ◽  
S Jhanwar ◽  
SA Ebrahim ◽  
D Filippa ◽  
BD Clarkson ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Cell Surfaces ◽  
Lambda Light Chain ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Immunodeficiency Virus

Abstract Of 187 specimens of non-Hodgkin's lymphoma and four hyperplastic lymphoid proliferations with clonal chromosome abnormalities ascertained serially over a 4 1/2-year period, nine cases with t(3;22)(q27;q11) were identified. Seven of the lymphomas were diffuse tumors, predominantly large cell type. The eighth tumor, a follicular small cleaved cell lymphoma, exhibited a t(3;22) and a t(14;18)(q32;q21). The ninth case was a lymph node from a human immunodeficiency virus-positive patient which showed atypical hyperplasia. Overall survival of t(3;22) diffuse lymphoma patients was not different from that of patients with abnormal karyotypes without t(3;22). The t(3;22) diffuse tumors studied showed a disproportionate frequency of lambda light chain on their cell surfaces, a finding similar to that observed in t(8;22)(q24;q11) Burkitt's lymphomas. Our results indicate that the t(3;22)(q27;q11) is the third most common recurring translocation in diffuse non-Hodgkin's lymphoma.

P-021: Hyponatremia in non-Hodgkin's lymphoma diffuse large B cell type of the elderly

2015 ◽  
Vol 6 ◽  
pp. S37
Author(s):  
N. Kazuhiko ◽  
S. Ishihara ◽  
D. Nagase ◽  
Y. Mitsui ◽  
A. Sakai ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
The Elderly ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

Hemophagocytic syndrome associated with non-hodgkin's lymphoma of B-cell type

1994 ◽  
Vol 47 (4) ◽  
pp. 335-336 ◽  
Author(s):  
Tetsuya Nakamoto ◽  
Seishi Ogawa ◽  
Hiroyuki Mano ◽  
Hisamaru Hirai ◽  
Yoshio Yazaki
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hemophagocytic Syndrome ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Two Resected Cases of Primary Pulmonary Non-Hodgkin's Lymphoma (B-cell, Diffuse, Small Cell Type).

Haigan ◽  
1993 ◽  
Vol 33 (7) ◽  
pp. 1083-1089
Author(s):  
Toshinori Hashizume ◽  
Keiichi Kikuchi ◽  
Toyohiko Tsurumi ◽  
Yotaro Izumi ◽  
Chikao Torikata
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Small Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study

Blood ◽  
1996 ◽  
Vol 88 (3) ◽  
pp. 1046-1051 ◽  
Author(s):  
ME Hill ◽  
KA MacLennan ◽  
DC Cunningham ◽  
B Vaughan Hudson ◽  
M Burke ◽  
...  
Keyword(s):  
B Cell ◽  
Relapse Rate ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Significance ◽  
Large Cell ◽  
Breakpoint Region ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Working Formulation

The Bcl-2 protein is capable of preventing apoptosis, and in vitro evidence suggests a role in drug resistance. It is expressed and the gene is rearranged in a proportion of cases of large-cell non-Hodgkin's lymphoma (NHL), but the clinical significance of these findings is controversial. The purpose of this study was to determine the influence of both Bcl-2 expression and major breakpoint region (MBR) bcl-2 rearrangement in a large cohort of prospectively accrued patients with intermediate-grade B-cell NHL treated in a standardized manner. All patients with Working Formulation F, G, or H NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in British National Lymphoma investigation studies between July 1974 and April 1992 were considered for this study if the appropriate paraffin blocks were available. Paraffin sections from the diagnostic specimen were analyzed for evidence of MBR rearrangement using a polymerase chain reaction-based method, and for Bcl-2 expression using immunohistochemistry. Failure to achieve complete remission (CR), relapse, death from NHL, and deaths from all causes were used as end points to measure CR rate, actuarial relapse rate, actuarial survival from NHL, and actuarial overall survival. One hundred sixty-one suitable patients were identified and tested for the bcl-2 MBR translocation, with 27 (17%) found to be positive; 153 of these patients were tested with immunocytochemistry, and 84 (55%) showed evidence of Bcl-2 expression. For patients who achieved CR from the initial treatment, the relapse rate was significantly higher in those with Bcl-2 expression than in those without. In addition, multivariate analysis identified Bcl-2 expression as the only factor significantly related to relapse rate in the subjects measured. The cause-specific survival for NHL in the series as a whole was significantly lower in patients with Bcl-2 expression than in those without. MBR status had no significant influence on any of the outcome measures, but the number of MBR-positive patients was relatively small, and larger studies are required. In conclusion, in Working Formulation F, G, and H NHL of B-cell type, expression of Bcl-2 protein predicted independently for relapse.

scholarly journals Mediastinal Non-Hodgkin's Lymphoma Metastatic to Right Atrium Mimicking Right Atrial Myxoma

2021 ◽  
Vol 57 (4) ◽  
pp. 345
Author(s):  
Gemilang Khusnurrokhman ◽  
Laksmi Wulandari
Keyword(s):  
B Cell ◽  
Right Atrium ◽  
Hodgkin’S Lymphoma ◽  
Atrial Myxoma ◽  
Hodgkin's Lymphoma ◽  
Right Atrial ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Right

Highlight:A 32-year-old male patient suffered mediastinal non-hodgkin's lymphoma metastatic to the right atrium which mimicked right atrial myxoma.The patient died of suspected mediastinal NHL thromboembolism that spread in the right atrium. Abstract:In this case report, the anatomical pathology results in the form of B cell type LNH, but at the age of 32 years and the risk factor in this patient was a former active smoker. In the anatomical pathology results, the results of the B-High Grade Cell Type LNH were also obtained. B-cell type non-hodgkin’s lymphoma can be mutated in the MYC gene (v-myc avian myceloctomatosis viral oncogene homolog) and the BCL-2 and BCL-6 (B-cell lymphoma) genes. If this morphology is found, then the patient's prognosis is poor. Most of these patients were males and the incidence was in the mediastinal area. Mediastinal NHL could develop and enlarge to involve the heart and pericardium. The spread could occur directly and lymphogens. These metastatic tumors were often misdiagnosed with atrial myxoma. In this case report, exploration of the right atrium and open mediastinal biopsy was performed. An open biopsy of the mediastinum revealed a mediastinal mass that enlarged to enter the right atrium. Atrial myxoma was not found. Primary lymphoma growth could also occur in the heart. This condition was called primary cardiac lymphoid (PCL). This case was very rare and was often considered an atrial myxoma. The patient died 10 days after discharge from the hospital. While the patient was eating, the patient had a seizure and the patient was immediately taken to the emergency department of Dr. Soetomo General Academic Hospital, Surabaya, and entered the ER (Resuscitation) ER room, but the patient died after being assisted for approximately two hours. Most likely the cause of the patient's death was a thromboembolic tumor in the right atrium that was released, so that it entered the bloodstream of the brain, causing the patient to have seizures. It was suspected that the cause of the patient's death was the presence of a tumor thrombus that separated into an embolism from the right atrium due to the large size of the tumor. Patients suffering from high rate NHL had a greater percentage of suffering from tumor thromboembolism as many as 10.6% compared to the Low type and Hodgkins lymphoma (LH) (5.8% and 7.25%).

scholarly journals t(3;22)(q27;q11): a novel translocation associated with diffuse non- Hodgkin's lymphoma [see comments]

Blood ◽  
1989 ◽  
Vol 74 (6) ◽  
pp. 1876-1879 ◽  
Author(s):  
K Offit ◽  
S Jhanwar ◽  
SA Ebrahim ◽  
D Filippa ◽  
BD Clarkson ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Cell Surfaces ◽  
Lambda Light Chain ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Immunodeficiency Virus

Of 187 specimens of non-Hodgkin's lymphoma and four hyperplastic lymphoid proliferations with clonal chromosome abnormalities ascertained serially over a 4 1/2-year period, nine cases with t(3;22)(q27;q11) were identified. Seven of the lymphomas were diffuse tumors, predominantly large cell type. The eighth tumor, a follicular small cleaved cell lymphoma, exhibited a t(3;22) and a t(14;18)(q32;q21). The ninth case was a lymph node from a human immunodeficiency virus-positive patient which showed atypical hyperplasia. Overall survival of t(3;22) diffuse lymphoma patients was not different from that of patients with abnormal karyotypes without t(3;22). The t(3;22) diffuse tumors studied showed a disproportionate frequency of lambda light chain on their cell surfaces, a finding similar to that observed in t(8;22)(q24;q11) Burkitt's lymphomas. Our results indicate that the t(3;22)(q27;q11) is the third most common recurring translocation in diffuse non-Hodgkin's lymphoma.

scholarly journals Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study

Blood ◽  
1996 ◽  
Vol 88 (3) ◽  
pp. 1046-1051 ◽  
Author(s):  
ME Hill ◽  
KA MacLennan ◽  
DC Cunningham ◽  
B Vaughan Hudson ◽  
M Burke ◽  
...  
Keyword(s):  
B Cell ◽  
Relapse Rate ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Significance ◽  
Large Cell ◽  
Breakpoint Region ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Working Formulation

Abstract The Bcl-2 protein is capable of preventing apoptosis, and in vitro evidence suggests a role in drug resistance. It is expressed and the gene is rearranged in a proportion of cases of large-cell non-Hodgkin's lymphoma (NHL), but the clinical significance of these findings is controversial. The purpose of this study was to determine the influence of both Bcl-2 expression and major breakpoint region (MBR) bcl-2 rearrangement in a large cohort of prospectively accrued patients with intermediate-grade B-cell NHL treated in a standardized manner. All patients with Working Formulation F, G, or H NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in British National Lymphoma investigation studies between July 1974 and April 1992 were considered for this study if the appropriate paraffin blocks were available. Paraffin sections from the diagnostic specimen were analyzed for evidence of MBR rearrangement using a polymerase chain reaction-based method, and for Bcl-2 expression using immunohistochemistry. Failure to achieve complete remission (CR), relapse, death from NHL, and deaths from all causes were used as end points to measure CR rate, actuarial relapse rate, actuarial survival from NHL, and actuarial overall survival. One hundred sixty-one suitable patients were identified and tested for the bcl-2 MBR translocation, with 27 (17%) found to be positive; 153 of these patients were tested with immunocytochemistry, and 84 (55%) showed evidence of Bcl-2 expression. For patients who achieved CR from the initial treatment, the relapse rate was significantly higher in those with Bcl-2 expression than in those without. In addition, multivariate analysis identified Bcl-2 expression as the only factor significantly related to relapse rate in the subjects measured. The cause-specific survival for NHL in the series as a whole was significantly lower in patients with Bcl-2 expression than in those without. MBR status had no significant influence on any of the outcome measures, but the number of MBR-positive patients was relatively small, and larger studies are required. In conclusion, in Working Formulation F, G, and H NHL of B-cell type, expression of Bcl-2 protein predicted independently for relapse.

scholarly journals Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma

Blood ◽  
1995 ◽  
Vol 86 (8) ◽  
pp. 2900-2905 ◽  
Author(s):  
PR Koduru ◽  
M Zariwala ◽  
M Soni ◽  
JZ Gong ◽  
Y Xiong ◽  
...  
Keyword(s):  
B Cell ◽  
Cytogenetic Analysis ◽  
Hodgkin’S Lymphoma ◽  
Large Cell ◽  
Homozygous Deletion ◽  
Hodgkin's Lymphoma ◽  
Wild Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Inhibitor Genes

B-cell non-Hodgkin's lymphoma (NHL) is a heterogeneous lymphoid malignancy consisting of several histologic types. Alterations in proto-oncogenes caused by reciprocal chromosome translocations have been implicated in the etiology of specific histologic groups. In this study, we examined the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors representing varied histologic groups. We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed from Hodgkin's disease. Tumor-specific point mutations were not identified in the coding regions of these genes. Cytogenetically, chromosome 9p was normal in all but one tumor. On the other hand, eight tumors hemizygous for 9p by cytogenetic analysis showed wild-type configuration of these genes. Our study, therefore, indicates that deletion of P15 and P16 occurs in about 15% of diffuse large-cell NHL and is not usually detected by cytogenetic analysis. P18 was wild-type in all tumors including the 13 tumors hemizygous for 1p.

Sign in / Sign up

Export Citation Format

Share Document